Aspen Neuroscience Advances the Automated Production of Personalized Autologous Cell Therapy for Parkinson's Disease
Aspen Neuroscience Advances the Automated Production of Personalized Autologous Cell Therapy for Parkinson's Disease
As part of this expansion, Aspen has entered into a collaboration agreement with Mytos, a leader in automated cell manufacturing, to focus on advancing plans to automate production of dopaminergic neuronal precursor cells (DANPCs) for ANPD001.Company is scaling out production of ANPD001 investigational cell therapy
公司正在扩大ANPD001临床电芯疗法的生产。
SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Aspen Neuroscience, Inc. has advanced its plans for automating production of ANPD001, including a capacity expansion for autologous manufacturing at its San Diego-based GMP facility. ANPD001, an investigational cell therapy program for treating people with Parkinson's disease (PD), is currently being studied in the company's ASPIRO Phase 1/2a clinical trial.
圣地亚哥，2025年1月8日 /PRNewswire/ -- Aspen Neuroscience, Inc. 已经推进其自动化生产ANPD001的计划，包括在其位于圣地亚哥的GMP设施中扩展自体制造的能力。ANPD001是一个针对帕金森病(PD)患者的临床电芯疗法项目，目前正在公司的ASPIRO 1/2a期临床试验中研究。
Designed and built for the manufacture and testing of ANPD001, this 22,000 square foot facility contains an additional 8,000 square feet to accommodate future automation.
该22,000平方英尺的设施专为ANPD001的制造和测试而设计和建造，另外还有8,000平方英尺的空间用于未来的自动化。
As part of this expansion, Aspen has entered into a collaboration agreement with Mytos, a leader in automated cell manufacturing, to focus on advancing plans to automate production of dopaminergic neuronal precursor cells (DANPCs) for ANPD001.
作为此次扩展的一部分，Aspen与自动化电芯制造的领先公司Mytos签署了合作协议，专注于推进自动化生产用于ANPD001的多巴胺能神经前体细胞(DANPCs)的计划。
Designed to replace lost dopamine-producing neurons in the brain, Aspen differentiates these DANPCs from patient-specific induced pluripotent stem cells (iPSCs), derived from the patient's own skin cells. This autologous approach has the potential of restoring lost function without the need for immunosuppressive drugs.
Aspen设计这些DANPCs以替代大脑中丢失的多巴胺产生神经元，这些细胞与从患者自身皮肤细胞衍生的特定患者诱导多能干细胞(iPSCs)不同。这种自体方法有可能在不需要免疫抑制药物的情况下恢复丢失的功能。
"This collaboration with Mytos addresses an important step for automating the manufacturing process for differentiation of DANPCs from induced pluripotent stem cells," explained Kim Raineri, Chief Technology Officer, Aspen Neuroscience. "The Mytos platform, combined with our bioinformatics and other enabling technologies, will allow us to further automate production of ANPD001 and treat greater numbers of patients with their own cells."
Aspen Neuroscience首席科技官Kim Raineri解释说：“与Mytos的这次合作解决了从诱导多能干细胞分化DANPCs的制造过程自动化的重要一步。” “Mytos平台结合我们的生物信息学和其他支持技术，将使我们进一步自动化ANPD001的生产，并治疗更多患者。”
ANPD001 is evaluated at every stage of manufacturing, utilizing Aspen's proprietary genomic platforms, a battery of in vitro and in vivo assays, and machine learning-based genetic tests to ensure the highest product quality.
ANPD001在制造的每一个阶段都进行了评估，利用Aspen的专有基因组平台、一系列体外和体内测试以及基于机器学习的基因测试，以确保产品的最高质量。
As part of its mission to deliver personalized cell therapies for patients with unmet medical needs, Aspen is driving innovative efforts to study, develop and manufacture iPSC-derived therapies, including the development of its autologous platform. The company recently announced plans for manufacturing scale-out, including its facility expansion, and a collaboration and license agreement with Cell X Technologies to advance the company's plans to automate the iPSC stage of the autologous cell manufacturing process.
作为其使命的一部分，Aspen致力于为有未满足医疗需求的患者提供个性化电芯疗法，推动创新努力研究、开发和制造基于iPSC的疗法，包括其自体平台的发展。该公司最近宣布了制造扩大计划，包括设施扩展，以及与Cell X Technologies的合作和许可协议，以推进公司自动化自体电芯制造过程中的iPSC阶段的计划。
About Aspen Neuroscience
关于Aspen Neuroscience
Headquartered in San Diego, Aspen Neuroscience, Inc. is a clinical development-stage, private company focused on autologous regenerative medicine. The company's patient-derived platform is used to create personalized cell therapies to address diseases with high unmet medical needs, beginning with autologous neuron replacement for PD. For more information and important updates, please visit
Aspen神经科学公司总部位于圣地亚哥，是一家临床开发阶段的私人公司，专注于自体再生医学。该公司的患者衍生平台用于创建个性化电芯疗法，以解决高未满足医疗需求的疾病，首个项目是自体神经元替代治疗帕金森病。有关更多信息和重要更新，请访问
About Mytos
关于Mytos
Mytos is a leader in automated cell manufacture. The company's platform enables life sciences companies to grow human cells with unparalleled precision and efficiency. Mytos has assembled a world-class team of engineers and scientists to develop an automated platform to accelerate the development of life-saving therapies. The company is based in London, UK. For more information, visit .
Mytos是自动化电芯制造的领先者。该公司的平台使生命科学公司能够以无与伦比的精确度和效率培养人类电芯。Mytos组建了一支世界级的工程师和科学家团队，以开发自动化平台，加速生命拯救疗法的开发。该公司总部位于英国伦敦。有关更多信息，请访问 .
SOURCE Aspen Neuroscience, Inc.
资料来源Aspen Neuroscience, Inc。
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想让贵公司的资讯在PRNEWSWIRE.COM上特色展示吗？
译文内容由第三方软件翻译。
